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Myelodysplastic SyndromeThe composition of the hematopoietic stem cell (HSC) niche within the bone marrow is highly dynamic, tightly
regulated, and of importance for various HSC properties. Integrins are importantmoleculeswithin this niche that
inﬂuence those properties through the interactions of HSCs and mesenchymal stem cells (MSCs). Here we
investigated the function of miR-134 in integrin regulation in MSCs. In MSCs, miR-134 post-transcriptionally
regulated β1 integrin expression. This negative regulation of β1 integrin was mediated by the binding of miR-
134 to its 3′ untranslated region, which contains two conserved binding sites for miR-134. The miR-134-
mediated silencing of β1 integrin in MSCs was shown by atomic force microscopy to decrease the adhesion of
32D cells to MSCs transfected with miR-134. Furthermore, the adhesion of MSCs to ﬁbronectin was reduced
after transfection with miR-134. MSCs from patients with myelodysplastic syndrome (MDS) revealed highly
signiﬁcant miR-134 overexpression compared with MSCs from healthy bone marrow donors. MSCs from MDS
patients showed lower β1 integrin protein, but not lower mRNA, expression, suggesting post-transcriptional
regulation. The present study demonstratesmiR-134-mediated negative regulation ofβ1 integrin that inﬂuences
cell adhesion to and of MSCs. These results further contribute to our understanding of the complexity of MDS.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
It was proposed several years ago that an existing hematopoietic
stem cell (HSC) niche controls cellular and molecular constituents to
maintain HSCs in balance between self-renewing and proliferative
states as well as to control homing and mobilization [1]. However, the
interplay of these niche components, including mesenchymal stem
cells (MSCs) [2], osteoblasts [3], non-myelinating Schwann cells [4],
and CXCL12-abundant reticular cells [5] on the one hand and
hematopoietic progenitors on the other remains unclear. Moreover,
variable concentrations of soluble factors, such as transforming growth
factor-β [6], CXCL-12, and stem cell factor [7], contribute to the
complexity of this environmental niche.eeting of the American Society
orgia, USA.
icine and Cardiology, University
, Germany. Tel.: +49 351 458
).
ights reserved.Integrins are one of the groups of molecules that intrinsically
modulate many physiological functions of hematopoietic niche cells.
Integrins are heterodimeric transmembrane cell adhesion receptors
consisting of α and β subunits. They are of great importance for the
attachment of cells to the extracellular matrix (ECM). They also
participate in cell–cell interactions [8,9]. While the β1 integrin subunit
might associatewith allα subunits, the latter determine binding afﬁnity
to short peptide sequences in ECM or collagens. Integrins are
bidirectional signaling receptors in which inside–outside signaling
through talins, kindlins, fokal adhesion kinase, integrin-linked kinase,
and others regulate integrin activation by converting integrins into
their active conformations. Upon ligand binding, conformational
changes in integrins activate outside–inside signaling, which is cell-
speciﬁc and depends on many cell-speciﬁc properties, but ultimately
leads to activation of cell proliferation, survival, and differentiation,
while inﬂuencing cellular properties such as migration, adhesion, and
polarity [10,11].
The physiological importance of β1 integrins for the hematopoietic
system is not precisely understood. Although several reports found no
major inﬂuence of β1 integrin on hematopoiesis in a murine model
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expression on interaction with MSCs, with consequences for cell cycle
regulation and differentiation of HSCs [14]. However, most studies have
investigated the inﬂuence of β1 integrin expression on HSC physiology.
Interestingly, it has recently been shown that integrins are highly
expressed on MSCs and that β1 integrin is the most abundant β integrin
on the surface of MSCs [15,16]. The integrin repertoire of cells is usually
highly dynamic and appears to be responsive to microenvironmental
conditions. The variable expression and activity ofβ1 integrin is therefore
obviously an important determinant of MSC function. However, the
precise regulatory events are incompletely understood.
Apart from the regulation of integrins through assembly in the cell
membrane, integrins are highly regulated at the transcriptional and
post-transcriptional levels. MicroRNAs (miRNAs) are one of these
post-transcriptional regulators within MSCs in the bone marrow
niche. miRNAs bind partially or completely to homologous sequences
within the 3′ untranslated region (3′UTR) of their respective mRNA
targets and repress their expression at the post-transcriptional level. It
is now estimated that two-thirds of human protein-coding genes are
signiﬁcantly regulated bymiRNAs [17,18]. Recently, Li et al. demonstrated
that β1 integrin expression is also modulated by miRNAs and that miR-
183 downregulatesβ1 integrin expression [19]. In addition to the binding
site for miR-183, the 3′UTR of β1 integrin harbors several putative
conserved binding sites for other miRNAs. One of these miRNAs, miR-
134, is involved in neuronal morphogenesis and differentiation and has
therefore been referred to as a brain-speciﬁc miRNA [20,21]. Recently, it
was demonstrated that MSCs from patients with myelodysplastic
syndrome (MDS) exhibit reduced β1 integrin expression and β1
integrin-mediated adhesion compared with MSCs from healthy bone
marrow donors, and that β1 integrins are essential for the regulation of
self-renewing hematopoietic precursor cells and maintenance of their
stemness [14,22].
The aim of this studywas to characterize the potential interactions of
miRNAswith the β1 integrin subunit inMSCs and a possible implication
inMDS. The experimentswere set up to use bothmolecular engineering
of MSC as well as investigations by atomic force microscopy (AFM) and
we aimed to study a highly homogenous population of cells. Therefore, a
model cell line, SCP-1 was used, that fulﬁlled both requirements. SCP-1
is a well-established human MSC cell line which has been recently
described to be comparable to primary humanMSC due to the potential
to undergo osteogenic and adipogenic differentiation. The cell line was
immortalized using constitutive overexpression of human telomerase
reverse transcriptase (hTERT) and is readily transfectable using standard
laboratory procedures [23].
2. Materials and methods
2.1. Cell cultures and MSC isolation
SCP-1 (immortalized MSC cell line) cells were cultured in MEMα
supplemented with 20% fetal calf serum (FCS) and 1% penicillin/
streptomycin as described recently [23]. The cells were split at 80–90%
conﬂuence. HeLa cells were cultivated in RPMI 1640 supplemented
with 10% FCS and 1% penicillin/streptomycin as described previously
[24]. 32D cells were cultured as described previously [25]. HS5, HS27A
and OP9 cells (ATCC) cells were cultivated in DMEM high glucose
medium, RPMI 1640 and MEMα respectively supplemented with 10%
FCS and 1% penicillin/streptomycin. Human CD34+ hematopoietic
stem cells were isolated from peripheral blood as described previously
[26]. Primary human MSCs were isolated and cultured as described
previously [27]. MSCs and CD34+ cells were derived from healthy
donors andMDS patients after receiving informed consent and approval
from the institutional review board (EK289112008). MSCs from
passages 2–4 were used for the experiments. The median ages of
healthy donors and MDS patients were 39 (20–66) and 65 (42–95)
years, respectively. MDS patients were classiﬁed according to theircytogenetic risk category as deﬁned by the International Prognostic
Scoring System (IPSS) for MDS patients [28].
2.2. Transfection of SCP-1 cells with siRNA and pre-miRNA
Transfection of SCP-1 cells was performed using a standard elec-
troporation protocol. In brief, 1 × 106 cells were resuspended in 100 μl
Nucleofactor Solution V (Lonza, Basel, Switzerland). Before electro-
poration, 1 μl of siRNA or pre-miRNA (100 pmol/reaction; Ambion,
Austin, TX, USA) was added to the resuspended cells. Electroporation
was performed using program X01 on a Nucleofactor I device (Lonza).
Electroporated cells were quickly transferred to 5 ml transfection
medium (MEMα with 20% FCS without antibiotics/antimycotics) and
seeded into cell culture plates.
2.3. RNA isolation and quantitative RT-PCR
Large and small RNAs were isolated using the mirVana™miRNA
Isolation Kit (Ambion) according to the manufacturer's protocol. Total
RNAs from primary MSC samples were isolated using Trizol reagent
(Life Technologies, Carlsbad, CA, USA). FirstChoice®Human Total RNA
Survey Panel (Ambion) was used for screening experiments.
Reverse transcription for detection of miRNA was performed using
the TaqMan MicroRNA Reverse Transcription Kit (Ambion) with the
respective miRNA-speciﬁc RT and PCR primer sets (TaqMan MicroRNA
Assays: U6:001973; miR-134:000459; Life Technologies).
cDNA synthesis was performed using SuperScript II Reverse Tran-
scriptase (Life Technologies) according to the manufacturer's protocol.
Quantitative PCRwas performed in duplicate using the TaqManUniversal
PCR Master Mix (Applied Biosystems). TaqMan Gene Expression Assays
(ITGβ1:Hs00236976_m1; GAPDH:4310884E; Life Technologies) were
used for quantiﬁcation. The PCR temperature proﬁle was as follows:
uracil-N-glycosylase incubation 2 min 50 °C, 10 min 95 °C; 50 cycles of
15s 95°C, 1min 60 °C. Data were analyzed using the 2−ΔΔct-method.
2.4. Western blotting
Total protein extracts were obtained as described previously [25].
30 μg of total protein was separated on an 8% denaturing SDS-
polyacrylamide gel. The proteins were blotted onto nitrocellulose
membranes (BD Biosciences, Franklin Lakes, NJ, USA). The membranes
were incubated with primary antibodies against β1 integrin (CD29,
mouse monoclonal, 1:500; BD Biosciences) and β-actin (rabbit
polyclonal, 1:4000; Sigma-Aldrich, St. Louis, MO, USA) in 5% non-fat
dry milk in TBST overnight. After washing, blots were probed with the
respective secondary antibodies for 1h. Western blots were developed
using the ECL Plus Chemiluminescence Detection Kit (GE Healthcare,
Uppsala, Sweden).
2.5. Adhesion assays
SCP-1 cells were transfected as described above. After transfection,
1.4 × 104 SCP-1 cells per well were cultured in a 96-well plate for 48 h.
32D cellswere labeledwith CellTracker™Red CMTPX (Life Technologies)
24 h before starting the adhesion assay. For adhesion assays, 3.6 × 104
32D cells were resuspended in MEMα and loaded over the transfected
SCP-1 layer. After 2 h incubation at 37 °C, the cocultured plates were
analyzed using a Mithras multimode microplate reader (Berthold
Technologies, Bad Wildbad, Germany). Removal of unattached and
weakly attached 32D cells was performed by supernatant removal and
three washing steps with phosphate-buffered saline. The remaining/
attached 32D cells were ﬁxed with 4% formaldehyde for 10 min at
room temperature. After the ﬁnal washing step, their ﬂuorescence was
measured, and relative ﬂuorescence units (RFU) were calculated.
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SCSF experiments were done using a NanoWizard II atomic
force microscope (AFM) equipped with a CellHesion module (JPK
Instruments, Berlin, Germany) mounted on an Axio Observer D1
(Zeiss, Jena, Germany). Detailed description of the method can
found in the supplement.
2.7. Cloning of β1 integrin 3′UTR and binding sites for miR-134
The 3′UTR of β1 integrin (2586–3796 bp from NM_002211.3)
was ampliﬁed from oligo-dT reverse-transcribed cDNA from human
macrophages using the following primer pair:ITG-β1 (SacI restriction site) senseTable 1
Oligonucleotides used for clo
Oligo name
ITG_miR134_bs1_wt_s
ITG_miR134_bs1_wt_as
ITG_miR134_bs1_mt_s
ITG_miR134_bs1_mt_as
ITG_miR134_bs2_wt_s
ITG_miR134_bs2_wt_as
ITG_miR134_bs2_mt_s
ITG_miR134_bs2_mt_as5′-TCCGAGCTC-ACTGTGGTCAATCCGAAG-3′
ITG-β1 (MluI restriction site) antisense 5′-GCACGCGT-TCCGATTTAAGTATTTTAGG-3′The PCR product was puriﬁed from an agarose gel following
digestion with SacI and MluI and ligated into a SacI/MluI-digested
pMIR-reporter vector (Ambion). The putative binding sites for miR-
134were identiﬁed using the PicTar [29] and TargetScan [30] prediction
algorithms on the basis of NM_002211. Thewild-type (wt) andmutated
(mt) binding sites were annealed and cloned into SpeI and HindIII sites
of the pMIR-reporter vector using the oligonucleotides (Euroﬁns MWG
Operon, Ebersberg, Germany) described in Table 1. For faster screening
of positive recombinants, the SpeI sitewasmutated (T➔A).Mutations of
the binding site were performed by mutation of the seed sequence to
adenosine. The identity of all clones was veriﬁed by sequence analysis
(Sequencing Facility, MPI-CBGDresden, Germany). Plasmid puriﬁcation
was performed using the Nucleobond Xtra Midi kit (Macherey-Nagel,
Düren, Germany) according to the manufacturer's instructions.
2.8. Transfection of HeLa cells and dual luciferase assay
HeLa cells (1 × 105 cells/well) were seeded in 24-well plates
(0.5 ml/well) 1 day before transfection. Cotransfection of the ﬁreﬂy
luciferase-containing pMIR reporter construct (1 μg), Renilla luciferase-
containing plasmid (pRL-CMV) (10 ng), and the pre-miRNA molecules
(preCo, pre-miR-134; 50 nM) was performed in duplicate by the
Lipofectamine 2000-based transfection method (Life Technologies).
The cells were lysed 48 h after transfection and the supernatant was
collected. The Dual-Luciferase®Reporter Assay System was used
according to the manufacturer's protocol (Promega, Madison, WI, USA).
Luminescencewasmeasured using a FLUOstar Optimamicroplate reader
(BMG Labtech, Ortenberg, Germany). Luciferase activity was normalized
to that in preCo-transfected controls.
2.9. FACS analysis
Cells (1 × 106) were ﬁxed and stained at 4 °C overnight with anti-
CD29-PE (mouse monoclonal, 1:5; BD Biosciences) or with mouse-
IgG1-PE (Beckman-Coulter, Brea, CA, USA) for isotype control. Acquisition
and analysis of the FACS data were performed using FACSCaliburning of the miR134 binding sites.
Sequence (5′➔3′)
CTAGA ACTGAATGCAAA
AGCTT CTGTGACTATGGA
CTAGA ACTGAATGCAAA
AGCTT CTTTTTTTATGGA
CTAGA GCCCATCTTGTTT
AGCTT ATGTGACTAGTGT
CTAGA GCCCATCTTGTTT
AGCTT ATTTTTTTAGTGTGcontrolled by CellQuest software (BD Biosciences). The β1 integrin
expression was determined as the geometric mean of the ﬂuorescence
intensities.
2.10. Bioinformatical structure analysis
The Sfold (http://sfold.wadsworth.org) algorithm was used to
calculate the accessibility of the predicted binding sites for miR-134
within the 3′UTR of β1 integrin [31]. The Sfold algorithm does not
predict a single secondary structure. It uses a set of secondary structures
distributed according to a Boltzmann distribution and applies this set of
structures to statistical analysis, which better reﬂects real secondary
structure of RNA [31,32].
2.11. Statistical analysis
Results were expressed as means ± standard error. Statistical
analysis was performed using paired Student's t-test. Differences
between the MDS patient groups were analyzed by ANOVA with the
Turkey post-hoc test. P values below 0.05 (*), 0.01 (**), and 0.001 (***)
were considered to be signiﬁcant, very signiﬁcant, and highly signif-
icant, respectively.
3. Results
3.1. Human β1 integrin gene contains several miRNA binding sites
The human β1 integrin gene was analyzed by in silico analysis using
the PicTar and the TargetScan algorithms [29,30]. This analysis revealed
several potential miRNA binding sites. Both algorithms predicted
binding sites for miR-29a/b/c (one binding site), miR-134 (two binding
sites), miR183 (two binding sites), and miR-223 (one binding site). In
addition, the PicTar algorithm identiﬁed three putative binding sites
for miR9* (Fig. 1A). In order to investigate the regulatory potential of
miRNAs in MSCs, basal β1 integrin protein expression in MSC cell lines
was analyzed. This comparison revealed strong expression β1 integrin
levels in SCP-1 cells (Fig. 1B). To analyze the effect of the above
identiﬁed miRNAs on β1 integrin expression, the respective pre-
miRNAs were transfected into SCP-1 cells. The analysis revealed strong
β1 integrin downregulation after transfection with pre-miR-134 (pre-
miR-134) and pre-miR-183. Transfectionwith pre-miR-223 led to slight
β1 integrin downregulation. Essentially, the same results were obtained
by transfecting the abovementioned pre-miR-molecules intoHeLa cells,
excluding an exclusive cell-speciﬁc effect in SCP-1 (Fig. 1C). Next, we
examined expression of these negatively regulating miRNAs in
primary human MSCs (n = 47) and found negligible expression of
miR-183 and miR-223 (data not shown). In contrast, miR-134
showed considerable expression in MSCs. Therefore, we focused on
analysis of miR-134-mediated β1 integrin downregulation. To
estimate the physiological distribution of miR-134 within different
tissues, we used the Ambion FirstChoice®Human Total RNA Survey
Panel. MSCs and CD34+ hematopoietic stem cells were also analyzed.
As reported previously, the highest miR-134 expression in the tested
tissues/cells was observed in the brain. The cervix, testis, and MSCs,Position
GTAGCAATTTCCATAGTCACAG A 2644–2676
AATTGCTACTTTGCATTCAGT T
GTAGCAATTTCCATAAAAAAAG A
AATTGCTACTTTGCATTCAGT T
CACACTAGTCACAT A 3675–3701
GAAACAAGATGGGC T
CACACTAAAAAAAT A
AAACAAGATGGGC T
Fig. 1.Human β1 integrin is regulated by miRNAs. (A): Putative binding sites for miRNAs (miR-9, miR-29, miR-134, miR-182, andmiR-223) were predicted by the PicTar and Targetscan
algorithm. (B): Human and mouse mesenchymal stem/stromal cell lines (SCP-1, Hs5, Hs27 and OP9) were screened for β1 integrin expression by western blotting (n = 3). (C): The
potential for miRNA-mediated silencing of β1 integrin by the predicted miRNAs was tested in SCP-1 and HeLa cells (n = 3). (D): miR-134 expression was quantiﬁed in different
human tissues and cells by real-time PCR.
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miR-134 was almost undetectable in CD34+ cells (Fig. 1D).
3.2. β1 integrin is negatively regulated by miR-134
The effect of miR-134 on β1 integrin expression was further
investigated. Transfection of SCP-1 cells with pre-miR-134 lead to 80-
fold overexpression of mature miR-134 (Supplementary Fig. S1).
Interestingly, this overexpression had no signiﬁcant effect on β1
integrin mRNA expression. Since transfection with siRNA targeting β1
integrin showed the expected downregulation, we could exclude an
inadequate functionality of the RNA interference machinery (Fig. 2A).
This was also supported by the fact that in contrast to the mRNA
expression, the transfection with pre-miR-134 signiﬁcantly decreased
β1 integrin protein expression (Figs. 1C and 2B). FACS-based analysis
ofβ1 integrin expression also showed signiﬁcantly decreased expression
in SCP-1 cells transfected with pre-miR-134 (Fig. 2C).
3.3. MiR-134 directly targets β1 integrin by binding to its 3′UTR
To determine whether miR-134 directly targeted β1 integrin by
binding to its mRNA, the complete 3′UTR was cloned into a ﬁreﬂy
luciferase-containing vector. HeLa cells were cotransfected with the
ﬁreﬂy luciferase-containing vector, Renilla luciferase-containing vector,and pre-miRNAs. To ensure that β1 integrin downregulation bymiR-134
also occurred in HeLa cells, β1 integrin protein expression after
transfectionwith pre-miR-134 and the respective controlswas analyzed.
This revealed strong repression ofβ1 integrin after transfectionwith pre-
miR-134 in HeLa cells (Fig. 1C). Cotransfection of the full-length 3′UTR-
containing vector with pre-miR-134 led to an approximately 50%
reduction (1.16 ± 0.04 vs. 0.58 ± 0.04) in ﬁreﬂy luciferase activity,
demonstrating a direct inﬂuence of miR-134 on the 3′UTR of β1 integrin
(Fig. 3A). A detailed analysis of the 3′UTR of the human β1 integrin
revealed two predicted binding sites (Figs. 1A and 3B). The ﬁrst binding
site is highly conserved in mammals, whereas the second binding site
appears to be poorly conserved (Fig. 3B left: PicTar-predicted miR-
134:β1 integrin duplexes). To estimate the secondary structure of the
human β1 integrin mRNA, the Sfold algorithm was applied to the full-
length sequence of β1 integrin and the accessibility of the nucleotides
within the predicted binding regions was calculated. Using this
calculation, we found that in both miR-134 binding sites there was a
high probability of single-stranded nucleotides occurring within the
seed sequence and in the regions where the PicTar algorithm predicted
binding of the miRNA. On the basis of this in silico analysis, the two
predicted miR-134 binding sites of the 3′UTR of β1 integrin were
further examined. Both binding sites (bs1_wt and bs2_wt) showed
reduced ﬁreﬂy luciferase activity after cotransfection with pre-
miR-134 compared with transfection with the precursor miRNA-
Fig. 2.MiR-134 regulates β1 integrin at a post-transcriptional level. (A): β1 integrin mRNA expression after transfection of SCP-1 cells with pre-miR-134 and a pre-control (preCo) in
comparison to siRNA-mediated silencing of β1 integrin (siITGb1) and the corresponding control siRNA (siCo) (n = 6). (B): β1 integrin protein expression was quantiﬁed by western
blotting and densitometric analysis in untreated SCP-1 cells and cells transfected with precursor control miRNA (preCo) and pre-miR-134 (n=4). (C): The degree of β1 integrin protein
repression by miR-134 was examined by FACS analysis 24 h after transfection (left: representative histogram plot of transfected SCP-1 cells (IgG served as negative control), right
quantiﬁcation of the data). The silencing of β1 integrin by a speciﬁc siRNA served as an internal control (n=5).
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mutating the seed sequence to all adenosines. In both instances, reduction
in ﬁreﬂy luciferase activity was blunted in the corresponding mutants
(bs1_mt and bs2_mt; Fig. 3C).
3.4. MiR-134 reduces the adhesion capacity of SCP-1 cells
Integrin signaling is associated with many cellular functions.
Therefore, different experimental approaches were applied to elucidate
the signiﬁcance of reduced β1 integrin; reduction occurred after
transfection with siRNA directed against β1 integrin (siITGb1) and
pre-miR-134. Pre-miR-134 overexpression did not inﬂuence the
proliferation rate of SCP-1 cells, as shown by BrdU incorporation and
Ki67 staining (Supplementary Figs. S2A and B). Interestingly, in
examining the migratory potential of transfected SCP-1 cells, we
detected slightly increased migration after transfection with siITGb1
and pre-miR-134 as demonstrated by the scratch assay (Supplementary
Fig. S2C). Because of the marginal modulation of these MSC properties,
we focused on the adhesion of SCP-1 cells. There were two possibilities.
First, miR-134 overexpressionmight affect the interaction of SCP-1 cells
with ECM. Second, β1 integrin downregulation by miR-134 could
modify the “niche function” of MSCs in their interaction with HSCs.
To analyze the role of miR-134 in β1 integrin-mediated adhesion to
ECM, SCP-1 cells were transfected with pre-miR-134 or siITGb1, while
control cells were transfected with preCo or a scrambled si-control
(siCo). AFM-based detachment force quantiﬁcation of transfected SCP-
1 cells on ﬁbronectin revealed that SCP-1 cells transfected with siITGb1
or pre-miR-134 showed signiﬁcantly reduced adherence compared
with the control cells (Fig. 4A).
Next, we examined the functional inﬂuence of miR-134 on the
interaction between SCP-1 cells and the hematopoietic cell line 32D,
which is of myeloid origin and has high expression of intrinsic vascular
cell adhesion protein 1 (VCAM-1), which is one of the ligands having a
high binding capacity to β1 integrin (data not shown). We ﬁrst applied
SCFS. The principle of the method is shown schematically in Fig. 4B.AFM-based detachment force quantiﬁcation of 32D cells on transfected
SCP-1 cells showed that SCP-1 cells transfected with siITGb1 or pre-
miR-134 showed a highly signiﬁcant reduction in adherence compared
with the control cells (Fig. 4C). Second, we investigated the adhesion
potential of 32D cells to SCP-1 cells by standard washing assays. After
transfection with siITGb1 or miR-134 molecules, SCP-1 cells were
coincubated with pre-labeled 32D cells. A signiﬁcantly lower adherence
of 32D cells to SCP-1 cellswas observed after transfectionwith pre-miR-
134 than that to the preCo-transfected SCP-1 control cells (Fig. 4D). 32D
cells co-incubated with siITGb1-transfected SCP-1 cells also showed
a signiﬁcant decrease in adherence compared with the cells co-
incubated with the control cells (Fig. 4D).
3.5. MSCs from MDS patients express higher levels of miR-134 and lower
levels of β1 integrin protein
We comparedmiR-134 expression levels inMSCs fromhealthy bone
marrow donors (n = 27) and from MDS patients (n = 18)
(Supplementary Table 1 for patient characteristics of all donors and
patients used for mRNA, miRNA and protein analysis). MSCs from
MDS patients had elevated miR-134 transcript levels (0.0127 ±
0.0011) compared with those from the healthy donors (0.0057 ±
0.0004; p b 0.0001). Equally signiﬁcant differences were observed
when comparing differentMDS risk groups to the healthy bonemarrow
donors in subgroup analyses performed with MSCs from MDS patients
with a deletion of chromosome 5q (del5q; n = 6), with MSCs from
high-risk MDS patients (n = 6), and with MSCs from low-risk MDS
patients (n= 6) (Fig. 5A). Interestingly, β1 integrin mRNA expression
was also signiﬁcantly higher in the del5q MDS patients and the high-
risk MDS patients (p b 0.001) but not in the low-risk MDS patients
compared with the healthy bone marrow donors (Fig. 5B). Since
miRNAs exploit their inhibitory activity at the post-transcriptional
level and given the elevated miR-134 expression in MDS patients, we
were interested in comparing β1 integrin protein expression between
the healthy bone marrow donors and MDS patients. Interestingly,
Fig. 3.MiR-134 regulatesβ1 integrin by interactionwith its 3′UTR. (A): To investigate whethermiR-134 directly regulatedβ1 integrin by interactingwith its 3′UTR, the complete 3′UTR of
human β1 integrin was cloned into the pMIR-reporter vector after the ﬁreﬂy luciferase stop codon. This plasmid was cotransfected with a Renilla luciferase-expressing vector under the
control of a CMV promoter and the pre-miRNA control (preCo) or pre-miR-134, and the luciferase activity wasmeasured 24h after transfection (n=6). (B): The predicted structures and
the calculated free energy of the miR-134:β1 integrin mRNA duplexes are illustrated (“|”, Watson–Crick base pairs; “:”, wobble base pairs). In addition, the Sfold algorithm was used to
calculate the target accessibility within the putative binding sites for miR-134. (C): The predicted binding sites were cloned as wild-type variants (bs1_wt, bs2_wt) or seed sequence-
mutated variants (bs1_mt, bs2_mt) downstream of the ﬁreﬂy luciferase gene of pMIR-reporter, and the luciferase activity was determined after cotransfection with a Renilla
luciferase-containing plasmid and preCo or pre-miR-134 (n=6).
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relative β1 integrin expression in MSCs from the MDS patients (n=5,
two patients with del5q MDS and three patients with high-risk MDS)
than in MSCs from the healthy bone marrow donors (n= 5; Fig. 5C).
These differences in mRNA and protein expression in MDS patients
further suggested post-transcriptional regulation.
4. Discussion
In this study, we investigated the role ofmiR-134 in the regulation of
β1 integrin expression in theMSC cell line SCP-1 and primaryMSCs.We
were able to show thatmiR-134 can bind to the 3′UTRofβ1 integrin and
that it regulates β1 integrin expression at a post-transcriptional level.This downregulation of β1 integrin leads to signiﬁcantly lower adhesion
of myeloid cells to SCP-1 and lower adhesion of SCP-1 to ﬁbronectin. In
addition, analysis of MSCs from MDS patients suggests a potential
relevance of this regulatory pathway in the disease.
In our ﬁrst experiments,MSC cell lineswere screened for β1 integrin
expression. SCP-1 cells expressed by far the highest levels of β1 integrin.
The sequence of the human β1 integrin mRNA was analyzed by two
independent in silico algorithms to identify potential binding sites for
miRNAs. The identiﬁed miRNAs were then investigated for their ability
to repress β1 integrin expression in SCP-1 and HeLa cells. As described
above, transient transfection with miR-134, miR-183, and miR-223
reduced β1 integrin. When we examined the basal expression of these
miRNAs in MSCs and SCP-1 cells under stable conditions, we did not
Fig. 4.MiR-134 transfection affects SCP-1 adhesion properties. (A): Atomic forcemicroscopy (AFM)-baseddetachment force quantiﬁcation of unmanipulated (Ø) or SCP-1 cells transfected
with siCo, siITGb1, preCo, or pre-miR-134 on ﬁbronectin. (B): Schematic description of single-cell force spectroscopy (SCFS) by AFM. (1) A 32D cell attached to a cantilever is placed above
an SCP-1 cell that is attached to aﬁbronectin-coated Petri dish. (2) Upon lowering, contact is induced for 40s. (3)Uponwithdrawal, adhesion, expressed as the necessary detachment force
(F0), is measured. (C): AFM-based detachment force quantiﬁcation of 32D cells by SCFS on SCP-1 cells transfected with siCo, siITGb1, preCo, or pre-miR-134. (D): SCP-1 cells were
transfected with pre-miR-134 or siITGb1, and control cells were transfected with preCo or siCo. The cells were coincubated with pre-labeled 32D cells. To determine the fraction of
adherent cells, standard adhesion wash assays were performed, and the relative ﬂuorescence units (RFU) for the quantiﬁcation of adherent 32D cells were calculated.
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was expressed in signiﬁcant amounts in these cells. Interestingly, Li
et al. recently showed that miR-183 regulates β1 integrin by targeting
its 3′UTR, demonstrating the importance of post-transcriptional regula-
tion of integrins [19]. These results were conﬁrmed by the present
study. Despite this regulation, other miRNAs have also been reported
to target β1 integrin [33,34]. Interestingly, Sekiya et al. identiﬁed miR-
29b to be inversely correlated with β1 integrin expression in hepatic
stellate cells [34]. In comparison to our results, where miR-29 did not
inﬂuence β1 integrin expression, this might exemplify a cell speciﬁc
regulation. But β1 integrin-signaling can also be modulated by
miRNA-mediated repression of dimerization partners. This was shown
recently formiR-31,which can regulate theβ1 integrin bindingpartners
α2,α5 andαV integrin [35]. However, the tissue screening formiR-134
showed enhanced expression in MSCs but not in HSCs. Recently, it was
shown that miR-134 is also expressed in the lung where it regulates
the lung septation process and can inﬂuence proliferation, apoptosis,
and migration [36]. Interestingly, all of these processes can also be
inﬂuenced by β1 integrin [9]. In addition, miR-134 was shown to be
upregulated in peripheral blood mononuclear cells from patients
with unstable angina pectoris, suggesting global expression and the
importance of miR-134 [37]. In addition to the regulatory mechanism
of direct targeting of β1 integrin bymiR-134, the present study expands
our knowledge of the cellular expression of miR-134 by demonstrating
that it is expressed in MSCs.
The notion that miR-134 downregulates β1 integrin in MSCs raised
further questions. We next investigated the physiological role of miR-
134 in the MSC cell line SCP-1 and found no inﬂuence of miR-134
overexpression on cell proliferation or migration. This was somewhat
unexpected because miR-134 is an efﬁcient regulatory molecule of β1
integrin in SCP-1 cells, and modiﬁcations in miR-134 could therefore
lead to reduced formation of focal adhesions and changes in proliferation.The ﬁndings are consistent with studies on signaling molecules were we
noticed no effect on phosphorylation of AKT and ERK and only a slight
decrease in FAK-phosphorylation upon miR-134 overexpression (data
not shown). However, we noticed a slight but non-signiﬁcant increase
in themigratory potentialwithmiR-134 overexpression andno inﬂuence
on proliferation (Supplemental Fig. S2). This could be related to previous
observations that described a critical inﬂuence onmigration/adhesion by
the optimal density of integrin or other adhesion molecules in contact
with ECM [38]. Interestingly, an epigenetic feedback-loop between
Galectin-3 and β1 integrins was demonstrated by Margadant et al.
which implies an existing Galectin-3 induction (through promoter
demethylation leading to transcriptional activation) during β1 integrin
induced epithelial-to-mesenchymal-transition [39]. We used the AFM-
based SCFS technology to analyze the individual contribution of miR-
134 regulation to β1 integrin-mediated cell–ECM contact and cell–cell
contact. We were able to show that miR-134 is capable of reducing the
adhesion capacity of 32D cells on MSCs. We also demonstrated that
MSCs themselves have lower capacity of adhesion to a ﬁbronectin layer
that was intended to simulate adhesion to an ECM component. Since
32D cells express the adhesion molecule VCAM-1, it is likely that the
adhesion is mediated by this member of the immunoglobulin super-
family. Furthermore, it has been reported that a subset of hematopoietic
and leukemic cells express VCAM-1, which makes them candidates for
interaction with β1 integrin on MSCs [40].
As every nucleated cell in the body, dependent on its direction of
differentiation, possesses a speciﬁc microRNA signature, the same is
true for integrins. The regulation of both appears to be very dynamic
and dependent on internal and external stimuli. Cell adhesion processes
mediated through β1 integrin appear to inﬂuence intracellular signaling
in order to maintain embryonic stem cells in an undifferentiated state
[41]. The results of these studies point to a role for β1 integrins as
anchoring motifs within the niche, which, if downregulated, could lead
Fig. 5.MiR-134 and β1 integrin expression differ between MDS patients and healthy bone marrow donors. β1 integrin and miR-134 expression were analyzed from MSCs from healthy
bonemarrowdonors andMSCs fromMDSpatients.MDS patientswere grouped according to their cytogenetic risk categories deﬁned by the International Prognostic Scoring System(IPSS)
for MDS patients [28]— detailed patient characteristics are depicted in Supplemental Table 1. (A): miR-134 expression in MSCs from healthy bone marrow donors and those from MDS
patients in different risk categories was determined by real-time RT-PCR. (B): β1 integrinmRNA expression inMSCs from the healthy bonemarrow donors and those fromMDS patients
was determined by real-time RT-PCR. (C): β1 integrin protein expression inMSCs fromhealthy bonemarrowdonors andMSCs fromMDS patients (n=5 for each group)was determined
bywestern blotting. Relative protein expression of β1 integrin was determined using densitometry and normalized to the β-actin controls in each sample. Representative blots are shown
for healthy bone marrow donors and MDS patients (one patient with del5q and two high-risk patients).
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Furthermore, the alteration in the adhesion capacity of MSCs to ECM
leads to changes in the differentiation potential andmay therefore disturb
the ability of MSCs to support HSCs in the niche [42,43].
While it is well known that MDS can lead to a gradual accumulation
of abnormal and dysfunctional HSCs, there is recent evidence that
alterations in the direct interaction of HSCs and MSCs contribute to MDS
development [44,45]. Furthermore, it has been demonstrated that MSCs
regulate the self-renewing capacity of HSCs through a β1 integrin-
dependentmechanism [14]. This, alongwith thewell-described phenom-
enonofmyelodysplastic transformation andprogression to acutemyeloid
leukemia of HSCs in the presence of the defective miRNA processing
machinery (the Dicer1 deletion in mesenchymal progenitors) [46], as
well as our ﬁndings, led us to study miR-134 and β1 integrin expression
proﬁles in MSCs derived from MDS patients. Interestingly, we were able
to show highly signiﬁcant miR-134 overexpression, along with signif-
icantly lower β1 integrin protein expression, in MSCs from the MDS
patients than in MSCs from the healthy bone marrow donors. While the
latter was recently reported [14,22], our observed deregulation of miR-
134 might explain the reduced β1 integrin expression in these patients.
Furthermore, a study ofMerkerova et al. showing an increased expression
of miR-134 in CD34+ cells in MDS patients is of great interest [47]. In
addition, it was shown that in patients with polycythemia vera, a chronic
myeloproliferative neoplasm of the bone marrow which is characterized
by a clonal proliferation of myeloid cells, the expression of miR-134 is
increased in CD34+ cells [48]. These studies in concert with the described
here let us hypothesize that miR-134 might play a crucial role in β1
integrin regulation in patients with MDS. Further studies will be
necessary to understand the functional relevance of lowered β1
integrin expression in MSCs from MDS patients. Although clinical
applications for restoring altered miRNAs in malignant diseases totheir original, healthy quantitative and functional signature remains
for the future, unraveling the functional consequences of altered
miRNA expression proﬁles are the utmost pivotal steps before their
role as therapeutic players can be determined.
In conclusion, the present study establishes an association between
miR-134 and β1 integrin expression and highlights the importance of
this regulatory circuit for the adhesion of HSCs on MSCs. The results
regarding downregulation of β1 integrin and upregulation of miR-134
inMDS patients may contribute to further understanding of the complex
pathophysiology of this heterogeneous disorder. The functional relevance
of miR-134 expression in MSCs from MDS patients warrants further
investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.10.003.
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